With 8.56 million shares changed hands, the volume of the stock remained lighter than its average volume of 15.08 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.71 whereas the lowest price it dropped to was $2.48. The 52-week range on ETHZ shows that it touched its highest point at $17.75 and its lowest point at $0.66 during that stretch. It currently has a 1-year price target of $1520.00. Beta for the stock currently stands at 0.42.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ETHZ was up-trending over the past week, with a rise of 0.80%, but this was up by 4.55% over a month. Three-month performance surged to 216.37% while six-month performance rose 187.50%. The stock gained 39.01% in the past year, while it has gained 64.29% so far this year.
Float and Shares Shorts:
At present, 164.45 million ETHZ shares are outstanding with a float of 121.27 million shares on hand for trading. On 2025-09-15, short shares totaled 7.2 million, which was 447.99999999999994 higher than short shares on 1753920000. In addition to Mr. McAndrew Rudisill BA(Econ) as the firm’s Executive Chairman & CEO, Mr. Eric R. Van Lent serves as its CAO, Principal Accounting & Financial Officer and Secretary of the Company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, ETHZ reported revenue of $0.0 and operating income of -$1730415.0. The EBITDA in the recently reported quarter was -$1723932.0 and diluted EPS was -$0.3.
